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Objectives This study sought to develop a 2-dimensional (2D) intravascular near-infrared fluorescence (NIRF) imaging strat-
egy for investigation of arterial inflammation in coronary-sized vessels.
Background Molecular imaging of arterial inflammation could provide new insights into the pathogenesis of acute myocardial
infarction stemming from coronary atheromata and implanted stents. Presently, few high-resolution approaches
can image inflammation in coronary-sized arteries in vivo.
Methods A new 2.9-F rotational, automated pullback 2D imaging catheter was engineered and optimized for 360° view-
ing intravascular NIRF imaging. In conjunction with the cysteine protease-activatable imaging reporter Prosense
VM110 (VisEn Medical, Woburn, Massachusetts), intra-arterial 2D NIRF imaging was performed in rabbit aortas
with atherosclerosis (n 10) or implanted coronary bare-metal stents (n  10, 3.5-mm diameter, day 7 post-
implantation). Intravascular ultrasound provided coregistered anatomical images of arteries. After sacrifice,
specimens underwent ex vivo NIRF imaging, fluorescence microscopy, and histological and immunohistochemi-
cal analyses.
Results Imaging of coronary artery–scaled phantoms demonstrated 8-sector angular resolution and submillimeter axial
resolution, nanomolar sensitivity to NIR fluorochromes, and modest NIRF light attenuation through blood. High-
resolution NIRF images of vessel wall inflammation with signal-to-noise ratios 10 were obtained in real-time
through blood, without flushing or occlusion. In atherosclerosis, 2D NIRF, intravascular ultrasound–NIRF fu-
sion, microscopy, and immunoblotting studies provided insight into the spatial distribution of plaque pro-
tease activity. In stent-implanted vessels, real-time imaging illuminated an edge-based pattern of stent-
induced arterial inflammation.
Conclusions A new 2D intravascular NIRF imaging strategy provides high-resolution in vivo spatial mapping of arterial inflam-
mation in coronary-sized arteries and reveals increased inflammation-regulated cysteine protease activity in
atheromata and stent-induced arterial injury. (J Am Coll Cardiol 2011;57:2516–26) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.036Thrombotic complications of atherosclerosis and implanted
coronary stents include myocardial infarction and sudden
cardiac death. Accordingly, there exists a compelling need
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stented arteries.
The biological characteristics of the arterial wall critically
influence atherogenesis and plaque thrombosis (1,2), as well
as the hyperplastic and thrombotic complications of arterial
stenting (3,4). Molecular imaging strategies now afford an
approach to reach beyond anatomy and visualize in vivo
atheroma inflammation, angiogenesis, apoptosis, oxidative
stress, and calcification (5,6). Yet, although, clinically fea-
sible for larger vessels such as the carotid and the aorta,
high-resolution clinical molecular imaging strategies for the
coronary arteries remain scarce, primarily due to the small
imaging target volume, and multiple sources of image
degradation, including cardiac and respiratory motion, and
blood flow.
In vivo near-infrared fluorescence (NIRF) visualization
approaches appear attractive for human coronary arterial
molecular imaging (7). A recent preliminary study demon-
strated 1-dimensional (1D) NIRF sensing (nonimaging) of
atheroma inflammation in small diameter (1.5 to 2.0 mm)
vessels (8). This approach, however, did not enable
2-dimensional (2D) imaging, nor sense NIRF signals in
vessels of diameters more typical of human coronary arteries
(2.5 to -3.5 mm), nor evaluate inflammation due to coronary
stent-induced injury. Additional limitations of the nonro-
tational 1D spectroscopic instrument included NIRF signal
detection from only a small sector of the entire 360° arterial
wall, limiting its sensitivity. In addition, the 1D system
Figure 1 Schematic of the Constructed 2D NIRF Imaging Syste
The tip of the fiber contains a right angle coated prism that reflects the guide’s la
fiber. The fluorescent light is then directed to a dichroic beam splitter that selectiv
mize the parasitic signals of laser photons and autofluorescence. The inset shows
near-infrared fluorescence.lacked longitudinal (axial) ana-
tomical accuracy due to manual
pullback and was subject to loss
of distal vessel access due to re-
quired pullback of the sensing
guidewire (as opposed to stan-
dard catheter-based imaging
approaches).
To address these limitations
and to advance the clinical po-
tential of intracoronary NIRF
molecular imaging, we present a
new 2D rotational and auto-
mated pullback NIRF intravas-
cular catheter apparatus, capable
of nanomolar-sensitive, intra-
arterial molecular imaging in
larger diameter coronary arteries.
We use the 2D NIRF catheter to provide new biological
insights into arterial inflammation in atheroma and coro-
nary stent-induced vascular injury in vivo.
Methods
Two-dimensional NIRF imaging device and catheter.
The apparatus (Fig. 1, Online Fig. 1) houses a continuous-
wave laser source operating at 750 nm (B&W Tek Inc.,
Newark, Delaware) with electronically adjustable output
Abbreviations
and Acronyms
1D  1-dimensional
2D  2-dimensional
FRI  fluorescence
reflectance imaging
IVUS  intravascular
ultrasound
NIRF  near-infrared
fluorescence
ROI  region of interest
SNR  signal-to-noise ratio
TBR  target-to-
background ratio
VM110  Prosense VM110
imaging agent
t into the artery wall and couples the subsequent fluorescent light back into the
ects it into a photomultiplier tube. The beam passes additional filters to mini-
pectra of the 3 filters (I, II, III) used in the system. 2D  2-dimensional; NIRF m
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ely refl
the s
N
m
i
a
o
a
b
R
fl
d
p
o
i
d
8
m
I
i
m
i
a
b
e
w
w
S
t
t
T
r
w
1
t
a
r
p
w
l
o
F
d
i
a
b
t
w
(
f
t
v
t
b
P
a
R
b
d
b
m
d
F
p
s
c
(
fi
D
a
D
S
a
(
L
b
W
c
t
t
s
i
m
a
R
I
a
N
g
t
p
m
s
s
a
2518 Jaffer et al. JACC Vol. 57, No. 25, 2011
Intravascular 2D NIRF Imaging of Inflammation June 21, 2011:2516–26power. The catheter consists of an optical fiber (numerical
aperture 0.37) within a polyethylene sheath (outer diameter
2.9-F) that guides the 750 nm laser light and collects the
subsequent NIRF emission. The fiber is rotated and trans-
lated using mechanical stages to collect fluorescence and
generate a 2D NIRF image. See Online Appendix for
supplemental methods, including phantom experiments.
Cysteine protease activity NIRF molecular imaging
agent. To image cysteine protease activity, an activatable
IRF imaging agent (Prosense VM110 [VM110], 0.5
g/kg, excitation/emission, 750 nm/780 nm, VisEn Med-
cal, Woburn, Massachusetts) was scaled up for use in
therosclerosis and arterial stent injury in rabbits. This class
f protease-activatable agents has been extensively validated,
nd cysteine protease activity, in particular cathepsin B, has
een reported on (8–10).
abbit atherosclerosis. Atherosclerotic lesions rich in in-
ammatory cells in New Zealand white rabbits were in-
uced by balloon injury and hypercholesterolemic diet as
erformed previously (8). Intravascular 2D NIRF imaging
f atheroma inflammation (n  10; n  7 VM110, n  3
saline) was performed at 8 weeks after injury. An additional
control group consisted of normal rabbits (n  2) injected
with VM110 (0.5 mg/kg) 24 h before imaging.
Stent-induced arterial injury. Bare-metal coronary stents
(3.5-mm diameter  12-mm length) were implanted into
the aorta of rabbits (n  10). Intravascular 2D NIRF
maging of stent-induced inflammation was performed at 7
ays after injury, 24 h after receiving Prosense VM110 (n
, 0.5 mg/kg) or saline (n  2). See the supplemental
ethods in the Online Appendix.
ntravascular NIRF and IVUS imaging. On the day of
maging, animals were anesthetized as described in the supple-
ental methods (Online Appendix). A 5-F introducer was
nserted into the right carotid artery using fluoroscopic and
ngiographic guidance. Iodinated contrast was injected and
aseline x-ray angiography was recorded using standard cin-
angiography. An intravascular ultrasound (IVUS) catheter
as inserted over a 0.014-inch guidewire and serial pullbacks
ere performed (Galaxy IVUS System, Boston Scientific/
cimed, Inc., Natick, Massachusetts) from the iliac bifurcation
o the renal arteries, with a pullback length of 100 mm. Next,
he monorail NIRF catheter was advanced over the guidewire.
o cover the entire IVUS-imaged vessel and understand
eproducibility of the NIRF signal profiles, the NIRF catheter
as advanced into the iliac artery and 3 to 4 contiguous,
10-mm length pullbacks were performed (rotational speed 30
o 100 rev/min). Animals were then euthanized and the iliac
nd aorta were resected. The NIRF catheter was gently
eintroduced into lumen of the aorta and ex vivo NIRF
ullbacks were repeated up to 3 times. Corresponding images
ere aligned using iliac bifurcation and renal arteries as
andmarks, and radiopaque catheter markers as fiducials. Areas
f plaque and normal vessel were confirmed by IVUS images.
luorescence reflectance imaging. Resected vessels un-
erwent multiple wavelength fluorescence reflectance imag- sng (FRI) (OV110, Olympus, Tokyo, Japan), equipped with
n NIR filter set (Omega Optical, Brattleboro, Vermont):
andpass excitation: 716 to 756 nm, bandpass emission: 780
o 820 nm. Multiple exposure times (0.1 to 60 s) for each
avelength and acquired images were exported as DICOM
Digital Imaging and Communications in Medicine) files
or further analysis. Due to vessel shrinkage after resection,
he aorta and the iliac vessels were manually elongated to in
ivo measured lengths. Regions of interest (ROIs) were
raced manually after visual identification of normal vessel,
ackground, plaque, and stented zones (Osirix version 2.7.5,
ixmeo, Switzerland). Stent ROIs included 3 mm of tissue
t the proximal and distal edge, respectively (total length of
OI drawn was 18 mm for 12-mm stent). Target-to-
ackground ratios (TBRs) were calculated for each ROI by
ividing the mean ROI signal of target by adjacent vessel
ackground (normal vessel). For SNR calculations, the
ean ROI signal of target was divided by the standard
eviation of background signal for each image.
luorescence microscopy. Fluorescence microscopy of
laque and normal vessel sections was performed on adjacent
ections from fresh-frozen rabbit arteries, and the images were
aptured and processed using an epifluorescence microscope
Eclipse 80i, Nikon Instruments, Melville, New York) with
lter sets for NIRF (excitation: 673 to 684 nm; dichroic mirror:
M750; emission: 765 to 835 nm; exposure time: 30 s) and
utofluorescence (excitation: 460 to 500 nm; dichroic mirror:
M505; emission: 510 to 560 nm; exposure time: 1 s).
tatistical analyses. In vivo signal-to-noise ratio (SNR)
nd TBR values were reported as median and quartiles
25th percentile, 75th percentile) (Prism 5.0c, GraphPad,
a Jolla, California). Statistically significant differences
etween 2 groups were determined using the Mann-
hitney U test for unpaired observations, and the Wil-
oxon matched-pairs signed-ranks test for paired observa-
ions. Among multiple groups, significance was assessed via
he Kruskal-Wallis test. A p value of 0.05 was considered
tatistically significant.
See the Online Appendix for supplemental methods for
n vivo atherosclerosis and stent NIRF SNR and TBR
easurements, NIRF-IVUS image fusion, histopathology,
nd immunoblotting.
esults
n vitro evaluation of a nanomole-sensitive rotational,
utomated pullback catheter platform for intravascular
IRF molecular imaging. In vitro performance (image
eneration, sensitivity, axial resolution, angular resolution) of
he 2D NIRF system was tested in custom-built coronary-scale
hantoms (Online Fig. 2). We first obtained SNR measure-
ents for various fluorochrome concentrations immersed in
aline and bloodlike solution, respectively (Figs. 2A and 2B). In
aline, a 100-nmol/l fluorochrome concentration was detected
t fiber-to-target distances of up to 4.5 mm. In the bloodlike
olution, the detected NIRF signal decayed exponentially with
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June 21, 2011:2516–26 Intravascular 2D NIRF Imaging of Inflammationdistance (d1/2  0.33 mm). The 50 mol/l and 100 nmol/l
NIRF phantoms were detected at fiber-to-target distances of
up to 2.5 and 1.2 mm, respectively. The overall system
sensitivity improved by an order of magnitude compared
with an earlier 2D prototype (11).
In saline, the angular resolution, or the ability to discern
discrete sectors along the circumference of the vessel, ranged
from 24° to 29° and was relatively unaffected by distance
(Fig. 2C). The angular resolution was lower in the bloodlike
solution (35° to 42°) due to light scattering, but still
demonstrated the ability to resolve 8 sectors at a fiber-to-
target distance of 3.0 mm. The axial resolution, or ability to
resolve fluorescence signals along the long axis of the vessel,
varied as a function of the fiber-to-target distance (Fig. 2D).
In blood, the resolution depended nonlinearly on the
fiber-to-target distance, reaching 1.0-mm resolution at a
2.0-mm fiber-to-target distance.
Intravascular NIRF high-resolution imaging of protease
activity in rabbit atheromata in blood-filled arteries. The
validated 2D NIRF catheter was then used to generate 2D
geometrically accurate maps of inflammation in atheroscle-
Figure 2 Evaluation of the 2D NIRF Apparatus in Coronary Arte
The signal-to-noise ratio (SNR) of the catheter for different fluorochrome concentra
olution of the system in saline and bloodlike solutions. The dashed line in A and B
distance from catheter-to-target; the fiber-to-target distance equals d  0.5 mm. Arosis. Twenty-four hours after injection of Prosense VM110
(n 7) or saline (n 3), atheroma-bearing rabbits (n 10)
underwent multimodality x-ray angiography, IVUS, and in
vivo NIRF imaging. In atherosclerotic animals injected with
VM110, in vivo NIRF catheter imaging revealed intense
focal signals along pullbacks, indicating elevated cysteine
protease activity (Fig. 3A). Ex vivo FRI confirmed high
NIRF signals within plaques (Figs. 3B and 3C). In contrast,
both saline-injected atherosclerotic and normal, VM110-
injected animals demonstrated reduced NIRF signals on in
vivo and ex vivo NIRF imaging (Figs. 3D to 3I). The ex
vivo vessel SNR was significantly greater in VM110-
injected atheroma-bearing rabbits than control atheroma/
saline rabbits and control normal/VM110 rabbits (median
[quartiles]: 229.1 [154.3, 311.6] vs. 90.2 [76.3, 90.5] and
83.6 [70.9, 96.2], p  0.01) (Fig. 4A). In the 2 atheroscle-
rosis groups (Figs. 4B and 4C), the ex vivo plaque SNR and
TBR were 140% higher in the VM110 group than in the
saline group (median [quartiles]: plaque SNR: 218.5 [194.3,
348.0] vs. 90.5 [77.9, 90.9], p 0.01; plaque TBR: 2.4 [2.0,
3.3] vs. 1.0 [1.0, 1.1], p  0.01).
ale Phantoms
easured in (A) saline and (B) bloodlike solutions. (C) Angular and (D) axial res-
gnates the sensitivity limit of the system, corresponding to SNR  4. d is the
ations as in Figure 1.ry Sc
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t
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p
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Intravascular 2D NIRF Imaging of Inflammation June 21, 2011:2516–26Radiopaque markers and vascular fiducials allowed reli-
able coregistration of intravascular NIRF and IVUS images
and demonstrated NIRF signal in areas of IVUS-
demarcated atherosclerosis (Fig. 5). Focality of NIRF signal
enhancement was appreciable in both the angular and axial
dimensions (Figs. 5D and 5E), which is consistent with
he eccentric, multifocal profile of IVUS-verified athero-
clerosis. Areas of normal-appearing vessel (lack of
laque detected by IVUS) demonstrated little NIRF
Figure 3 In Vivo High-Resolution NIRF Molecular Imaging of Cy
(A) Aorta from atherosclerotic (athero) rabbits injected with Prosense VM110 (VisE
cular near-infrared fluorescence (NIRF) catheter. (B) Ex vivo fluorescence reflectan
from atherosclerotic rabbits injected with saline and imaged in vivo with the NIRF
(G) Normal rabbit injected with VM110 and imaged with the intravascular NIRF cat
vivo and ex vivo fluorescence images were equally windowed and processed (color
Figure 4 Ex Vivo NIRF Reflectance Imaging Analyses of Athero
The 3 experimental groups tested were: atherosclerosis  Prosense VM110 (Athe
VM110 (Normal/VM110), where Prosense VM110 is a protease-activatable NIRF i
(C) plaque SNR from the 3 experimental groups. *p  0.05. Abbreviations as in Fbackground signal. The Prosense VM110 group showed
significantly higher vessel SNR in vivo, with 170%
increase over to the other 2 control groups (p  0.04)
(Fig. 6A). In rabbits with atheromata, the in vivo plaque
SNR and TBR was 450% higher in the VM110 group
than in the saline group (median [quartiles]: SNR: 12.6
[8.1, 20.6] vs. 1.3 [0.9, 2.1], p  0.02; TBR: 6.3 [4.3,
9.4] vs. 1.1 [0.9, 1.4], p  0.02) (Figs. 6B and 6C). In
addition, augmented NIRF proteinase signal also ap-
e Proteinase Activity in Atherosclerosis
ical, Woburn, Massachusetts) 1 day earlier and imaged in vivo with the intravas-
ging (FRI) at 800 nm and (C) ex vivo NIRF–white light fusion image. (D) Aortas
er, and (E) ex vivo FRI at 800 nm and (F) ex vivo NIRF–white light fusion image.
(H) Ex vivo FRI at 800 nm (1 s) and (I) ex vivo NIRF–white light fusion image. In
p table applies to all images in each row). Scale bar: 10 mm.
flammation
110), atherosclerosis  saline (Athero  saline), and normal  Prosense
g agent. (A) Ex vivo vessel SNR, (B) plaque target-to-background ratio (TBR), and
1 and 2.stein
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ce ima
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June 21, 2011:2516–26 Intravascular 2D NIRF Imaging of Inflammationpeared in an area of injury-induced arterial dissection
adjacent to atheroma (Online Fig. 3).
Elevated in vivo and ex vivo plaque NIRF signal associ-
ates with the cysteine protease cathepsin B. Advanced
plaques and early plaques (Figs. 7A and 7B) demonstrated
strong cathepsin B immunoreactivity within the intima and
media, consistent with augmented proteinase expression
Figure 5 Representative In Vivo Molecular and Anatomical Ima
(A) Angiographic appearance (with inset high magnification image in dotted yellow
tion, enabling coregistration with intravascular ultrasound (IVUS). (B) Angiogram o
firming its intravascular position (yellow). (C) Longitudinal IVUS image of the abdo
(P1, P2). (D) Image of NIRF catheter pullback aligned with the angiogram and IVUS
ies. Corresponding 1-dimensional plot of the angle-averaged 2D NIRF intensity pul
white  strongest NIRF signal intensity, red/black  lowest NIRF signal intensity
minimally stenotic atherosclerotic plaques. (H, I) Axial IVUS images from zone P1(precursor and mature form) within macrophages andsmooth muscle cells (12,13). Intimal cathepsin B staining
colocalized with immunohistochemical detection of
RAM-11 positive intimal macrophages. In contrast, the
normal vessel wall produced minimal cathepsin B and
macrophage staining (Fig. 7C).
Fluorescence microscopy revealed focal NIR fluorescence
in the intima of advanced plaques (Fig. 7A). Early athero-
of Inflamed Atheromata
) of radiopaque tip of NIRF catheter positioned just proximal to the iliac bifurca-
therosclerotic iliac and aorta. Tip of the NIRF catheter at pullback initiation con-
aortoiliac arteries. Arrows demarcate IVUS-detectable mildly stenotic plaques
demonstrates NIRF signal in small volume plaques, in 3.0-mm-diameter arter-
elow. (E) Longitudinal superimposed NIRF and IVUS fusion images (yellow/
) High magnification image of plaque zones P1 and P2. Arrows indicate
. Abbreviations as in Figure 1.ging
lines
f the a
minal
image
lback b
). (F, G
and Pmata with cathepsin B enzyme presence (Fig. 7B) did not
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Intravascular 2D NIRF Imaging of Inflammation June 21, 2011:2516–26emit NIRF, which suggests lower cysteine protease activity
in early stage plaques. Fluorescence microscopy further
revealed that the NIRF signal was plaque-specific and
VM110-specific, as autofluorescence signal (535-nm fluo-
rescence) colocalized with elastin-rich medial fiber signals.
Slight medial autofluorescence was visualized in the 800-nm
channel and, as expected, was substantially lower than
autofluorescence at 535 nm (14,15). Immunoblotting of
Figure 6 NIRF Signal Analyses of Atheroma Inflammation Dete
(A to C) In vivo plaque TBR, SNR, and vessel SNRs from atherosclerotic animals
(Athero  saline), or from normal (nonatherosclerotic) animals injected with Prose
Figure 7 Histopathological and Immunoblotting Assessments o
In each row, the 5 images depict correlative arterial sections of hematoxylin and e
active cathepsin B (catB, 20), near-infrared fluorescence (NIRF) at 800 nm, and
by cysteine protease activation of Prosense VM110, and blue color denoting signa
active macrophages and cathepsin B, and intimal NIRF protease activity signals ar
the intima and media but little NIRF cysteine protease activity (800-nm image). (C
color) on fusion fluorescence microscopy images. (D) Cathepsin B and beta-actin
sin B in atherosclerotic aortas. Pro-catB denotes the 46 kD pre-cathepsin B band,normal and plaque-rich aorta showed increased expression
of both precursor and mature cathepsin B protein in
plaque-rich vessels (Fig. 7D).
Intravascular NIRF molecular imaging of coronary
stent-induced arterial inflammation reveals a stent edge-
based injury pattern in vivo. Extended arterial inflamma-
tion characterizes unhealed coronary stents that may pro-
voke stent thrombosis (3,4). To investigate and image
In Vivo by the 2D NIRF Catheter
d with either Prosense VM110 (Athero  VM110) or saline
110 (normal  VM110). *p  0.05. Abbreviations as in Figures 1, 2, and 4.
tic Inflammation
H&E) staining (10), immunoreactive macrophages (RAM-11, 20), immunore-
d 800-nm–535-nm fluorescence, with red color denoting 800-nm signal induced
35 nm originating from autofluorescence. (A) In an advanced plaque, immunore-
ent. (B) Early stage atheroma demonstrates macrophages and cathepsin B in
ion of a normal artery. Elastin fibers provide a source of autofluorescence (blue
oblot of lysates from normal and plaque-containing vessel demonstrates cathep-
ature catB denotes the 25 kD and 30 kD cathepsin B bands.cted
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June 21, 2011:2516–26 Intravascular 2D NIRF Imaging of Inflammationarterial wall inflammation in vivo following stent deploy-
ment, New Zealand White rabbits underwent aortic balloon
injury (N  10) followed by deployment of a bare-metal
coronary stent (3.5  12 mm). Six days following stent
implantation, rabbits received intravenous Prosense VM110
(n  8) or saline (n  2). The next day (day 7) rabbits
nderwent in vivo multimodality x-ray angiography, IVUS,
nd intravascular NIRF imaging. In stent-injured vessels,
ncreased in vivo NIRF signal localized at the edges of the
mplanted stents, and particularly at the leading or distal
tent edge (Fig. 8), suggesting that stent-based injury
ccurred at sharp transition points. In addition, as aug-
ented protease signal was noted 1 to 2 mm away from the
tent edge, another mechanism of vessel wall inflammation
ould be due to balloon extension (“overhang”) injury at the
roximal and distal stent edges. Intriguingly, very high
agnification ex vivo FRI of the resected coronary stents
evealed increased cysteine protease activity at the greater
urvature of stent struts (Figs. 9C to 9E).
The maximal SNR occurred at stent edges and was
ignificantly greater than uninjured vessel segments for both
n vivo NIRF pullbacks (median [quartiles]: 23.1 [11.7,
7.0] vs. 1.1 [1.0, 3.7], p  0.02) and ex vivo FRI (median
quartiles]: 234.5 [160.6, 274.2] vs. 110.7 [100.7, 135.0],
 0.008) (Figs. 9F and 9G). The maximum stent TBR
as 18.3 [2.8, 25.7] in the VM110 group versus 1.2 [1.0,
.4] in the saline group (p  0.056) for the in vivo NIRF
ullbacks. Immunoblot analyses also revealed augmented
athepsin B proteases in extracts of injured vessel wall
ncasing implanted coronary stents (Fig. 9H).
iscussion
omplications of atherosclerosis and improperly healed coro-
ary stents include acute myocardial infarction and sudden
ardiac death. To address the unmet clinical need for high-
esolution molecular imaging strategies targeted to coronary-
ized arteries, we engineered and validated an intravascular
atheter-based 2D NIRF imaging platform. The intravascular
olecular imaging results demonstrate spatial mapping of
rterial inflammation (as mediated by VM110 activation and
uorescence generation following cleavage by cysteine pro-
eases) in atherosclerosis, as well as in coronary-stent induced
ascular injury and arterial dissection. Anatomically accurate
mages were obtained in real-time, through blood, and without
he need for flushing or occlusion.
The optimized 2D NIRF imaging system demonstrated
everal advantages in vivo compared with a prior guidewire
evice (8) and a recent less-sensitive 2D prototype (11) that did
ot support in vivo molecular imaging. These advantages
nclude: 1) the ability to obtain 2D molecular images of
ultifocal vascular inflammation with 360° coverage and ac-
urate geometry; 2) the ability to image vascular inflammation
n blood-filled arteries of 3.5-mm diameter, which is signifi-
antly larger than demonstrated previously (1.5 to 2.0 mm) (8),
hereby offering greater applicability to vessels of the caliber of auman coronary arteries; 3) coregistration of high-resolution
VUS that enabled fusion molecular-anatomical imaging; and
) implementation of a clinical-type 2.9-F monorail catheter
hat avoids loss of distal vessel guidewire access.
Intravascular NIRF can image biological processes of
mportance in atherosclerosis and stent healing including
nflammation, angiogenesis, fibrin deposition, and remod-
ling (16). In atherosclerosis, inflammation is a key biolog-
cal process that promotes atherogenesis and plaque rupture,
nd it characterizes high-risk, vulnerable plaques (1). In
articular, proteinases participate as key mediators of in-
ammation, facilitating matrix degradation, remodeling,
eukocyte recruitment, and elastic lamina breakdown. In
onjunction with the NIRF molecular imaging agent
rosense VM110, the intravascular NIRF catheter enabled
igh-resolution imaging of cysteine proteinase activity in
theromata, stent injury, and intimal dissection induced by
rterial intervention. Subsequent histological and biochem-
cal analyses linked the NIRF signal to cysteine proteases, a
arker of inflamed plaques. In addition, fluorescence mi-
roscopy revealed differences between NIRF imaging of
nzyme activity and immunohistochemical detection of
nzyme presence (Fig. 7). In contradistinction to the more
xtensive immunoreactive cathepsin B protein in the intima
nd media of early and advanced atheroma, NIRF-detected
ysteine protease activity was restricted to the diseased
ntima of more established atheromata. Unlike IVUS and
ther structural imaging methods, NIRF imaging of ather-
ma assesses the activity of cathepsin B and related enzymes
nd, hence, provides insight into the in vivo biology of
nflamed plaques.
Stent thrombosis, a clinical syndrome that often causes
cute myocardial infarction and cardiac death, may occur
rom incompletely healed coronary stents, typically charac-
erized by impaired endothelialization, inflammation, and
brin deposition (3,4). At present, few approaches can
isualize biological aspects of coronary-stent induced injury
n vivo. The employed 2D NIRF strategy provided new
nsights into in vivo arterial inflammation following implan-
ation of bare-metal coronary stents in rabbit aortas (Fig. 8).
he stent edges showed higher proteinase activity signal,
nd high-magnification ex vivo FRI demonstrated protei-
ase activity largely on the outer (greater) curvature of the
mployed bare-metal stent. This effect may result from
ifferential flow-mediated inflammation related to the con-
guration of the stent strut (17). The observed edge-based
nflammatory injury patterns in vivo further support that
tent geometry, design, and materials influence the risk of
tent thrombosis and restenosis (18). Further studies may
hed light on the differences in the temporal-spatial patterns
f arterial inflammation surrounding implanted drug-
luting stents compared with implanted bare-metal stents.
tudy limitations. A limitation to the current intravascular
IRF approach is surface-weighting of the NIRF signal as
function of fiber-to-wall distance, particularly in light-ttenuating blood. This aspect limits the depth resolution of
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Intravascular 2D NIRF Imaging of Inflammation June 21, 2011:2516–26Figure 8 Representative Multimodality NIRF Molecular and IVUS Anatomical Imaging
of Arterial Inflammation at Day 7 Following Coronary Stent Implantation
(A) Angiogram of an implanted bare-metal stent in the abdominal aorta. Dotted rectangle denotes stent position. (B, C) Longitudinal IVUS and NIRF catheter pullbacks
demonstrate NIRF signal within the stent. NIRF signal collection was performed through blood without flushing, in 3.5-mm diameter vessels. (D) Corresponding 1-dimensional
plot of the angle-averaged 2D NIRF signal at each axial point. (E) Longitudinal IVUS and NIRF fusion image (yellow/white  strongest NIRF signal intensity, red/black  lowest
NIRF signal intensity). (F to H) Axial IVUS images from percutaneous transluminal coronary angioplasty alone, stent, and normal vessel zones, respectively. Abbreviations as in
Figures 1 and 5.
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June 21, 2011:2516–26 Intravascular 2D NIRF Imaging of Inflammationthe NIRF signal, as well as optimal signal quantification for
noncentered catheters. Possible compensation methods in-
clude the use of a focused fiber to image a more selective
tissue volume, as well as mapping the luminal position of
the NIRF catheter from coregistered IVUS information, as
a first approximation, to correct the NIRF signal based on
the fiber-to-wall distance. Of note is that plaque tissue is
less likely to attenuate NIRF signals, based on prior tissue
phantom studies (8). Additional sensitivity gains are antic-
Figure 9 NIRF Imaging of Stent Injury
(A) Ex vivo FRI at 800 nm reveals augmented NIRF protease activity at stent edge
NIRF signal increases. (C) Ex vivo NIRF–white light fusion image of the stent, (D)
along the greater curvature of stent struts. (F) In vivo and (G) ex vivo SNR in the n
staining in normal and stented rabbit aorta. Pro-catB denotes the 46 kD pre-cathe
bar: 10 mm. *p  0.05. Abbreviations as in Figures 1, 2, and 3.ipated with the use of focused and larger numerical aperturefibers to deliver and collect light more efficiently. Finally, to
enable accurate angular NIRF and IVUS coregistration, a
limitation of the 2 separate NIRF and IVUS catheters, as
well as additional strategies employing 3-dimensional ra-
diopaque fiducials may be helpful.
Conclusions
From a translational standpoint, intracoronary NIRF mo-
Corresponding ex vivo intravascular NIRF pullback also detected stent-based
agnification white light, and (E) high-magnification NIRF image reveals signal
and stented aorta (paired observations). (H) Immunoblot of cathepsin B (catB)
band, and mature catB denotes the 25 and 30 kDa cathepsin B bands. Scales. (B)
high-m
ormal
psin Blecular imaging via optical catheters appears clinically viable,
2526 Jaffer et al. JACC Vol. 57, No. 25, 2011
Intravascular 2D NIRF Imaging of Inflammation June 21, 2011:2516–26based on U.S. Food and Drug Administration approval of
other light-based catheter approaches including optical
coherence tomography/optical frequency domain imaging
(19) and NIR spectroscopic chemical imaging (20) using
similar laser powers and catheter sizes. In addition, clinical
approval of NIRF imaging agents appears promising based
on the favorable safety profile of indocyanine green (21), a
clinical NIR fluorochrome widely used in retinal angiogra-
phy and historically in cardiac output studies. Clinical use of
such novel imaging technologies will naturally first require
safety studies of new NIRF imaging agents and intravascu-
lar catheters.
Ultimately, high-resolution molecular imaging of coro-
nary arteries could provide a new approach to: 1) investigate
the natural history of inflammation in a variety of coronary
arterial pathologies, including atherosclerosis, stent-induced
vascular injury, dissection, arteritis and allograft vasculopa-
thy; 2) investigate novel pharmacotherapies designed to
attenuate inflammation in coronary atherosclerosis; and
3) to provide an in vivo biological framework to identify
subjects with high-risk plaques and high-risk coronary
stents predisposed to thrombosis.
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